Letter to WTO Condemning Failure to Waive IP Rules
Letters PDF • 2022TAG and 300 NGOs worldwide condemn the U.S., U.K., E.U., & Switzerland for blocking an intellectual property waiver for purposes of global COVID-19 vaccine production. In light of this shameful failure, we urge countries to act outside of WHO structures to save lives.
New Rifapentine Formulations at New Prices: No Excuses for Not Scaling-Up TB Preventive Treatment
Statement / Press • 2022We, the undersigned civil society and community-based organizations, welcome the announcement by Unitaid and its partners that they have reached an agreement with Lupin Limited and Macleods Pharmaceuticals to introduce two formulations of rifapentine at competitive prices.
Long-Acting Therapy for Malaria Prevention: Toward a Malaria-Free World
TAGline • 2021By Joelle Dountio Ofimboudem Malaria is a life-threatening disease prevalent in the world’s poorest countries, particularly in sub-Saharan Africa. Preventing malaria hits close to home for me. I am a mother to two children, aged three and five. We are originally from Cameroon, where we all have contracted malaria multiple times. As an intellectual property…
Substantial Public Investments in GeneXpert Underscore Need for Affordable Pricing
Statement / Press • 2021TAG’s comprehensive analysis found that the public invested at least $252 million USD in the research and development of GeneXpert diagnostic technology, which stands in stark contrast to the lack of affordable pricing and favorable service and maintenance terms from the diagnostics company Cepheid.
Launch of Public Health Partnership to Tackle the Silent Epidemic of Hepatitis C in Low- and Middle-Income Countries
Statement / Press • 2021The Drugs for Neglected Diseases initiative (DNDi), Médecins Sans Frontières (MSF), FIND, the global alliance for diagnostics, and the Treatment Action Group are joining forces to tackle a ‘silent’ public health injustice: the continuing disparities in access to diagnostics and treatment for the hepatitis C virus (HCV) in low- and middle-income countries (LMICs), home to 75% of those living with this viral illness.
US FDA COVID Vaccine Authorization Important Step Toward Ending the COVID-19 Pandemic
Statement / Press • 2020Today’s decision by the US Food and Drug Administration (FDA) to grant an Emergency Use Authorization (EUA) for the Pfizer-BioNTech mRNA vaccine is an important step toward bringing the COVID-19 pandemic under control in the United States.
Story: American Gene Technologies HIV Gene Therapy
Page • 2019November 2019 Examples of media coverage: Gene Tech Company Claims to Have Found a Cure for HIV/AIDS – NewNowNext, November 8, 2019 Researchers believe they’ve found the cure for HIV/AIDS – Pink News, November 8, 2019 Research Lab Believes They Have HIV/AIDS Cure – Instinct Magazine, November 7, 2019 American Gene Technologies believes they have the cure for HIV/AIDS – LocalDVM.com, November 6,…Follow-Up Letter: Serious Concerns RE: Errors in the WHO Guidelines for the Treatment of Drug-Resistant TB
Letters PDF • 2019Follow-Up Letter: Serious Concerns RE: Errors in the WHO Guidelines for the Treatment of Drug-Resistant TB TAG and the other allied civil society organizations who sent the original letter (below) didn’t receive an adequte response to our original letter, so on June 5 we sent a follow up to Dr. Tedros Adhanom Ghebreyesus.
Story: Live Attenuated SHIV Vaccine Associated with Virus Clearance in Macaques
Page • 2019November 2021 Examples of media coverage:Â Research team develops vaccine that kills HIV in monkeys – The Asahi Shimbun, November 9, 2021 A New Vaccine Kills HIV in Monkeys. And It’s Coming to Humans in 5 Years – Interesting Engineering, November 11, 2021 HIV breakthrough offers hope as new vaccine crushes virus in stunning trial…Protestors Demand Cepheid Halve the Price of GeneXpert TB Tests to US$5
Statement / Press • 2019The high cost of GeneXpert tests for tuberculosis (TB) leaves open a critical gap in the diagnosis of TB and fails to consider volume of sales and public investments in the development of GeneXpert.